Abrocitinib is an orally available, small molecule inhibitor of Janus kinase 1 (JAK1) that is used to treat moderate-to-severe atopic dermatitis. Abrocitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has not been linked to cases of clinically apparent acute liver injury.